Ironwood Pharmaceuticals Earnings Estimate
| IRWD Stock | USD 4.86 0.08 1.62% |
Ironwood Pharmaceuticals Revenue Breakdown by Earning Segment
By analyzing Ironwood Pharmaceuticals' earnings estimates, investors can diagnose different trends across Ironwood Pharmaceuticals' analyst sentiment over time as well as compare current estimates against different timeframes. At present, Ironwood Pharmaceuticals' Operating Profit Margin is projected to slightly grow based on the last few years of reporting. The current year's Net Profit Margin is expected to grow to 0, whereas Gross Profit is forecasted to decline to about 221.3 M. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Ironwood Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.
Ironwood Pharmaceuticals Earnings Estimation Breakdown
The calculation of Ironwood Pharmaceuticals' earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Ironwood Pharmaceuticals is estimated to be 0.213325 with the future projection ranging from a low of 0.1025 to a high of 0.275. Please be aware that this consensus of annual earnings estimates for Ironwood Pharmaceuticals is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
0.10 Lowest | Expected EPS | 0.28 Highest |
Ironwood Pharmaceuticals Earnings Projection Consensus
Suppose the current estimates of Ironwood Pharmaceuticals' value are higher than the current market price of the Ironwood Pharmaceuticals stock. In this case, investors may conclude that Ironwood Pharmaceuticals is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Ironwood Pharmaceuticals' stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of December 2026 | Current EPS (TTM) | |
| 4 | 57.48% | 0.0 | 0.213325 | 0.18 |
Ironwood Pharmaceuticals Earnings per Share Projection vs Actual
Actual Earning per Share of Ironwood Pharmaceuticals refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Ironwood Pharmaceuticals predict the company's earnings will be in the future. The higher the earnings per share of Ironwood Pharmaceuticals, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.Ironwood Pharmaceuticals Estimated Months Earnings per Share
For an investor who is primarily interested in generating an income out of investing in entities such as Ironwood Pharmaceuticals, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Ironwood Pharmaceuticals should always be considered in relation to other companies to make a more educated investment decision.Ironwood Quarterly Analyst Estimates and Surprise Metrics
Earnings surprises can significantly impact Ironwood Pharmaceuticals' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
null | null | null | null | null | 0 | ||
null | null | null | null | null | 0 | ||
2025-11-10 | 2025-09-30 | 0.11 | 0.24 | 0.13 | 118 | ||
2025-08-11 | 2025-06-30 | 0.03 | 0.14 | 0.11 | 366 | ||
2025-05-07 | 2025-03-31 | 0.2 | -0.14 | -0.34 | 170 | ||
2025-02-13 | 2024-12-31 | 0.0775 | 0.02 | -0.0575 | 74 | ||
2024-11-07 | 2024-09-30 | 0.08 | 0.02 | -0.06 | 75 | ||
2024-08-08 | 2024-06-30 | 0.15 | -0.0054 | -0.1554 | 103 | ||
2024-05-09 | 2024-03-31 | 0.19 | -0.02 | -0.21 | 110 | ||
2024-02-15 | 2023-12-31 | 0.21 | -0.01 | -0.22 | 104 | ||
2023-11-09 | 2023-09-30 | 0.16 | 0.09 | -0.07 | 43 | ||
2023-08-08 | 2023-06-30 | 0.25 | 0.31 | 0.06 | 24 | ||
2023-05-04 | 2023-03-31 | 0.24 | 0.25 | 0.01 | 4 | ||
2023-02-16 | 2022-12-31 | 0.27 | 0.27 | 0.0 | 0 | ||
2022-11-03 | 2022-09-30 | 0.27 | 0.28 | 0.01 | 3 | ||
2022-08-04 | 2022-06-30 | 0.3 | 0.21 | -0.09 | 30 | ||
2022-05-05 | 2022-03-31 | 0.26 | 0.21 | -0.05 | 19 | ||
2022-02-17 | 2021-12-31 | 0.35 | 0.27 | -0.08 | 22 | ||
2021-11-04 | 2021-09-30 | 0.31 | 0.33 | 0.02 | 6 | ||
2021-08-05 | 2021-06-30 | 0.23 | 0.34 | 0.11 | 47 | ||
2021-05-06 | 2021-03-31 | 0.21 | 0.24 | 0.03 | 14 | ||
2021-02-17 | 2020-12-31 | 0.29 | 0.36 | 0.07 | 24 | ||
2020-11-05 | 2020-09-30 | 0.15 | 0.23 | 0.08 | 53 | ||
2020-08-06 | 2020-06-30 | 0.09 | 0.16 | 0.07 | 77 | ||
2020-05-06 | 2020-03-31 | 0.05 | 0.04 | -0.01 | 20 | ||
2020-02-13 | 2019-12-31 | 0.24 | 0.3 | 0.06 | 25 | ||
2019-10-31 | 2019-09-30 | 0.11 | 0.4 | 0.29 | 263 | ||
2019-07-30 | 2019-06-30 | -0.03 | 0.1 | 0.13 | 433 | ||
2019-05-02 | 2019-03-31 | -0.14 | -0.26 | -0.12 | 85 | ||
2019-02-13 | 2018-12-31 | -0.15 | -0.02 | 0.13 | 86 | ||
2018-11-06 | 2018-09-30 | -0.17 | -0.38 | -0.21 | 123 | ||
2018-08-06 | 2018-06-30 | -0.21 | -0.28 | -0.07 | 33 | ||
2018-05-01 | 2018-03-31 | -0.23 | -0.27 | -0.04 | 17 | ||
2018-02-15 | 2017-12-31 | -0.18 | -0.14 | 0.04 | 22 | ||
2017-11-02 | 2017-09-30 | -0.22 | -0.18 | 0.04 | 18 | ||
2017-08-03 | 2017-06-30 | -0.22 | -0.3 | -0.08 | 36 | ||
2017-05-08 | 2017-03-31 | -0.2 | -0.36 | -0.16 | 80 | ||
2017-02-21 | 2016-12-31 | -0.24 | -0.09 | 0.15 | 62 | ||
2016-11-03 | 2016-09-30 | -0.23 | -0.23 | 0.0 | 0 | ||
2016-08-04 | 2016-06-30 | -0.15 | -0.14 | 0.01 | 6 | ||
2016-05-09 | 2016-03-31 | -0.13 | -0.09 | 0.04 | 30 | ||
2016-02-18 | 2015-12-31 | -0.17 | -0.09 | 0.08 | 47 | ||
2015-11-03 | 2015-09-30 | -0.2 | -0.25 | -0.05 | 25 | ||
2015-08-05 | 2015-06-30 | -0.22 | -0.34 | -0.12 | 54 | ||
2015-05-05 | 2015-03-31 | -0.23 | -0.24 | -0.01 | 4 | ||
2015-02-12 | 2014-12-31 | -0.21 | -0.27 | -0.06 | 28 | ||
2014-11-04 | 2014-09-30 | -0.32 | -0.3 | 0.02 | 6 | ||
2014-08-04 | 2014-06-30 | -0.36 | -0.44 | -0.08 | 22 | ||
2014-04-29 | 2014-03-31 | -0.43 | -0.38 | 0.05 | 11 | ||
2014-01-21 | 2013-12-31 | -0.5 | -0.43 | 0.07 | 14 | ||
2013-10-22 | 2013-09-30 | -0.57 | -0.51 | 0.06 | 10 | ||
2013-07-23 | 2013-06-30 | -0.68 | -0.57 | 0.11 | 16 | ||
2013-04-23 | 2013-03-31 | -0.64 | -0.82 | -0.18 | 28 | ||
2013-01-15 | 2012-12-31 | -0.47 | -0.41 | 0.06 | 12 | ||
2012-10-16 | 2012-09-30 | 0.13 | 0.42 | 0.29 | 223 | ||
2012-07-17 | 2012-06-30 | -0.32 | -0.38 | -0.06 | 18 | ||
2012-05-01 | 2012-03-31 | -0.24 | -0.34 | -0.1 | 41 | ||
2012-02-28 | 2011-12-31 | -0.11 | -0.07 | 0.04 | 36 | ||
2011-11-07 | 2011-09-30 | -0.21 | -0.21 | 0.0 | 0 | ||
2011-08-11 | 2011-06-30 | -0.19 | -0.19 | 0.0 | 0 | ||
2011-05-12 | 2011-03-31 | -0.17 | -0.19 | -0.02 | 11 | ||
2011-03-03 | 2010-12-31 | -0.14 | -0.12 | 0.02 | 14 | ||
2010-11-04 | 2010-09-30 | -0.19 | -0.08 | 0.11 | 57 | ||
2010-08-05 | 2010-06-30 | -0.19 | -0.18 | 0.01 | 5 | ||
2010-05-11 | 2010-03-31 | -0.16 | -0.25 | -0.09 | 56 | ||
2010-03-30 | 2009-12-31 | -0.2 | -3.3 | -3.1 | 1550 |
About Ironwood Pharmaceuticals Earnings Estimate
The earnings estimate module is a useful tool to check what professional financial analysts are assuming about the future of Ironwood Pharmaceuticals earnings. We show available consensus EPS estimates for the upcoming years and quarters. Investors can also examine how these consensus opinions have evolved historically. We show current Ironwood Pharmaceuticals estimates, future projections, as well as estimates 1, 2, and three years ago. Investors can search for a specific entity to conduct investment planning and build diversified portfolios. Please note, earnings estimates provided by Macroaxis are the average expectations of expert analysts that we track. If a given stock such as Ironwood Pharmaceuticals fails to match professional earnings estimates, it usually performs purely. Wall Street refers to that as a 'negative surprise.' If a company 'beats' future estimates, it's usually called an 'upside surprise.'
Please read more on our stock advisor page.| Last Reported | Projected for Next Year | ||
| Retained Earnings | -1.5 B | -1.5 B | |
| Retained Earnings Total Equity | -626.7 M | -658.1 M | |
| Price Earnings Ratio | 720.75 | 756.79 | |
| Price Earnings To Growth Ratio | (9.20) | (8.74) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Ironwood Pharmaceuticals is a strong investment it is important to analyze Ironwood Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Ironwood Pharmaceuticals' future performance. For an informed investment choice regarding Ironwood Stock, refer to the following important reports:Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Ironwood Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. For information on how to trade Ironwood Stock refer to our How to Trade Ironwood Stock guide.You can also try the Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.
Will Biotechnology sector continue expanding? Could Ironwood diversify its offerings? Factors like these will boost the valuation of Ironwood Pharmaceuticals. Market participants price Ironwood higher when confident in its future expansion prospects. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Ironwood Pharmaceuticals data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Quarterly Earnings Growth 10.468 | Earnings Share 0.18 | Revenue Per Share | Quarterly Revenue Growth 0.333 | Return On Assets |
Investors evaluate Ironwood Pharmaceuticals using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Ironwood Pharmaceuticals' intrinsic value—the estimated true worth—helps identify when the stock trades at a discount or premium to fair value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. External factors like market trends, sector rotation, and investor psychology can cause Ironwood Pharmaceuticals' market price to deviate significantly from intrinsic value.
Please note, there is a significant difference between Ironwood Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Ironwood Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Conversely, Ironwood Pharmaceuticals' market price signifies the transaction level at which participants voluntarily complete trades.